Shares of Twist Bioscience Corp (NASDAQ: TWST) plummeted 19.53% in Friday's trading session, following the release of its fiscal 2025 fourth-quarter results and 2026 guidance. The synthetic DNA technology company's mixed performance and conservative outlook triggered a significant sell-off among investors.

For the fourth quarter ended September 30, 2025, Twist Bioscience reported a net loss of $0.45 per share, missing the analyst consensus estimate of $0.43 loss per share. This wider-than-expected loss overshadowed the company's revenue beat, which came in at $99.009 million, surpassing expectations of $97.317 million and marking a 16.88% increase from the previous year.

Adding to investor concerns, Twist Bioscience's fiscal 2026 guidance fell short of market expectations. The company forecasts total revenue for fiscal 2026 to be in the range of $425 million to $435 million, compared to the FactSet consensus estimate of $431.9 million. This cautious outlook, combined with the earnings miss, has led investors to reassess the company's growth trajectory and profitability prospects, resulting in the sharp stock price decline.